Department of Defense Fiscal Year 2004 Neurofibromatosis Research Program (NFRP) Clinical Trial Award

The summary for the Department of Defense Fiscal Year 2004 Neurofibromatosis Research Program (NFRP) Clinical Trial Award grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Dept of the Army USAMRAA, which is the U.S. government agency offering this grant.

Department of Defense Fiscal Year 2004 Neurofibromatosis Research Program (NFRP) Clinical Trial Award: The intent of Clinical Trial Awards is to sponsor patient-oriented research with the potential to have a major impact on the treatment and/or management of NF1, NF2, and/or Schwannomatosis. Clinical Trial Awards will support Phase I and Phase II clinical trials; separate discussions are provided below for each type of clinical trial. Applicants should clearly specify in their proposals for which type of Clinical Trial Award they are applying. The ultimate goal of the Clinical Trial Award mechanism is to sponsor novel clinical research that has the potential to substantially improve today?s approach to the treatment and management of NF1, NF2, and/or Schwannomatosis. Participating institutions must be willing to resolve potential intellectual property issues and to remove institutional barriers that might interfere with achieving high levels of cooperation to ensure the successful completion of the clinical trials. An intellectual property plan agreed upon by all participating institutions is required as part of the administrative documentation of this proposal (see V.E.14). Please note that all Department of Defense (DOD)-funded research involving human subjects and/or human anatomical substances must be reviewed and approved by the Human Subjects Research Review Board (HSRRB) in addition to local Institutional Review Boards (IRBs). It is recommended that all protocols be prepared according to the guidelines provided in the document titled ?Research Involving Human Subjects and/or Anatomical Substances,? which can be found at https://cdmrp.org/programAnnouncements.cfm under ?Regulatory Document Forms.? An HSRRB-approved template for clinical protocols also can be found at this site.